Evidence map›Paper›PMID 35096574›Full record

ReviewFrontiers in oncology2021

Anti-Hepatocellular Carcinoma Effect and Molecular Mechanism of the Estrogen Signaling Pathway.

Yusheng Guo, Guohui Wu, Junrong Yi, Qin Yang, Wengong Jiang, Shaoqiang Lin, Xiaorong Yang, Xiangsheng Cai, Liufeng Mao

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed, 1 pooled it
2.8field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed, 1 synthesis or guideline pooled it, 32 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yusheng GuoScientific Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Guohui WuScientific Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Junrong YiScientific Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Qin YangNephrology Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Wengong JiangNephrology Department, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Shaoqiang LinScientific Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Xiaorong YangClinical Laboratory, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
Xiangsheng CaiCenter for Medical Experiments, University of Chinese Academy of Science-Shenzhen Hospital, Shenzhen, China.
Liufeng MaoScientific Research Center, The First Affiliated Hospital of Guangdong Pharmaceutical University, Guangzhou, China.
First Affiliated Hospital of Guangdong Pharmaceutical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

There are significant gender differences in the incidence and mortality of hepatocellular carcinoma (HCC). Compared with men, the incidence and mortality of HCC in women are relatively low. The estrogen signaling pathway, composed of estrogen and estrogen receptors, has been postulated to have a protective effect on the occurrence and development of HCC. There have been multiple studies that have supported anti-HCC effects of the estrogen signaling pathways, including direct and indirect pathways such as genomic pathways, rapid transduction pathways, non-coding RNA, tumor microenvironment, estrogen metabolites, and inhibition of hepatitis infection and replication. Based on the evidence of an anti-HCC effect of the estrogen signaling pathway, a number of strategies have been investigated to determine the potential therapeutic effect. These have included estrogen replacement therapy, targeting the estrogen receptor, key molecules, inflammatory mediators, and regulatory pathways of the estrogen signaling pathway. In this review, we have systematically summarized the latest developments in the complex functions and molecular mechanisms of the estrogen signaling pathway in liver cancer. Furthermore, we have highlighted the potential targets of treatment strategies based on the estrogen signaling pathway in the treatment of liver cancer and the principal obstacles currently encountered for future investigation.

Indexed as

estrogen receptorestrogen signaling pathwayhepatocellular carcinoma (HCC)molecular mechanismtumor therapy

Identifiers

PMID35096574
PMCPMC8789654
OpenAlexW4205616305

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.